Inovio’s coronavirus vaccine candidate delivers promising results in Phase 1 trial

• Inovio released a coronavirus vaccine update to announce that its experimental DNA drug generated immune responses in 94% of volunteers enrolled in Phase 1 trials.
• The company is part of the US government’s Operation Warp Speed initiative to fast-track the development of COVID-19 vaccines.
• A Phase 2/3 trial will follow this summer, pending regulatory approval.

---

Inovio Pharmaceuticals kicked off the Phase 1 trial of its INO-4800 coronavirus vaccine candidate in early April, and the company has good news to report for the first stage of testing.

The DNA vaccine is funded in part by the Bill and Melinda Gates Foundation, and it’s included in the US government’s Operation Warp Speed initiative to speed up COVID-19 vaccine research. The drug delivered promising results, the company said in a press release, with 94% of volunteers having developed the expected immune response following two doses of the drug. Moreover, a separate preclinical animal challenge study revealed the drug can prevent viral replication in the lungs in mice that were infected with the virus.

Continue reading...

Today's Top Deals

1. Today’s top deals: Purell hand sanitizer, Honeywell face masks, Purell wipes, $5 smart plugs, huge SanDisk sale, more
2. Amazon has 62¢ reusable face masks with a special antimicrobial coating
3. Secret sale scores you a Fire TV Stick 4K for less than an entry-level Fire TV Stick

Trending Right Now:

1. We might finally know why the coronavirus spread is out of control again
2. CDC provides another excuse to avoid American Airlines like the plague
3. The case for more stimulus checks just got much stronger

Inovio’s coronavirus vaccine candidate delivers promising results in Phase 1 trial originally appeared on BGR.com on Tue, 30 Jun 2020 at 23:18:37 EDT. Please see our terms for use of feeds.

from BGR https://ift.tt/31vpHjg